Načítá se...
Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
Hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2 negative) breast cancer accounts for over 70% of all breast cancers. There has been much advancement in the treatment of HR+/HER2 negative metastatic breast cancer (MBC), in particular the development of more tail...
Uloženo v:
| Vydáno v: | Breast Cancer (Dove Med Press) |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7680678/ https://ncbi.nlm.nih.gov/pubmed/33239910 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BCTT.S219436 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|